Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Capital Expenditures: 2019-2025

Historic Capital Expenditures for Keros Therapeutics (KROS) over the last 7 years, with Sep 2025 value amounting to $132,000.

  • Keros Therapeutics' Capital Expenditures fell 65.80% to $132,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 21.85%. This contributed to the annual value of $1.9 million for FY2024, which is 21.63% down from last year.
  • As of Q3 2025, Keros Therapeutics' Capital Expenditures stood at $132,000, which was down 81.67% from $720,000 recorded in Q2 2025.
  • Over the past 5 years, Keros Therapeutics' Capital Expenditures peaked at $1.1 million during Q1 2023, and registered a low of $132,000 during Q3 2025.
  • For the 3-year period, Keros Therapeutics' Capital Expenditures averaged around $528,364, with its median value being $541,000 (2023).
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 1,721.43% in 2021, then slumped by 65.80% in 2025.
  • Quarterly analysis of 5 years shows Keros Therapeutics' Capital Expenditures stood at $159,000 in 2021, then spiked by 120.75% to $351,000 in 2022, then surged by 54.13% to $541,000 in 2023, then tumbled by 46.58% to $289,000 in 2024, then slumped by 65.80% to $132,000 in 2025.
  • Its Capital Expenditures stands at $132,000 for Q3 2025, versus $720,000 for Q2 2025 and $565,000 for Q1 2025.